Eupraxia Pharmaceuticals sets up at-the-market share sales program with Jefferies under US$300M shelf

Eupraxia Pharmaceuticals entered an Open Market Sale Agreement dated November 10, 2026 with Jefferies LLC and Jefferies Securities, Inc. It allows the company to issue and sell common shares from time to time on Nasdaq and the TSX, at a 3% selling commission. The program is drawn from the company's Canadian short form base shelf prospectus of up to US$300 million, with the British Columbia Securities Commission as principal regulator.

10 Nov 2026 · Eupraxia Pharmaceuticals Inc. EPRX · Company news

Company's press release (SEC filing): Eupraxia Pharmaceuticals Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Eupraxia Pharmaceuticals sets up at-the-market share sales program with Jefferies under US$300M shelf

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq